FdaApplication
NDA 202123
Identifiers
- fda_app_no: NDA202123
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2011-08-10 |
Revenue by product
COMPLERA
| Period | Revenue |
|---|---|
| Q4 2023 | $25.0M* |
| Q3 2023 | $34.0M* |
| Q4 2022 | $58.0M* |
| Q3 2022 | $43.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| COMPLERA | EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE | 200MG;EQ 25MG BASE;300MG | TABLET;ORAL |
1 product